Tirzepatide - SURMOUNT-2, SURMOUNT-3 and SURMOUNT-4 On July 27, 2023, Eli Lilly and Company announced results of SURMOUNT-3 and SURMOUNT-4 in adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes
Who Shouldnt Use Semaglutide
Is tirzepatide fatigue different from semaglutide fatigue
For instance, tirzepatide, a dual-target agonist of GLP-1R/GIPR, has shown superior glucose-lowering effects than semaglutide in phase III clinical trial 8
Pen-sharing poses a risk for transmission of blood-borne pathogens Hypoglycemia: Patients receiving Ozempic in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia
You may need to lessen your dosage for your next dose in order to minimize risk and/or severity of potential side effects